Becker's Healthcare September 21, 2022
Pharmaceutical companies have years to find loopholes in the Inflation Reduction Act — a law recently signed that aims to lower drug costs — and legal experts say the delayed implementation could hinder its goals, NBC News reported Sept. 20.
The legislation, totalling $739 billion, was signed into law Aug. 16. Its terms include capping Medicare’s insulin prices at $35 per month starting in 2023, limiting out-of-pocket Medicare costs to $2,000 per month in 2025 and allowing the FDA to negotiate prices for 10 drugs in 2026.
Because it will take four years for the IRA to be fully implemented, some health policy experts are concerned about the various strategies drugmakers can use to bypass the law.
“Trying...